A new paradigm of quantifying ecosystem stress through chemical signatures

Stress-induced emissions of biogenic volatile organic compounds (VOCs) from terrestrial eco- systems may be one of the dominant sources of VOC emissions worldwide. Understanding the ecosystem stress response could reveal how ecosystems will respond and adapt to climate change and, in turn, quan- tify changes in the atmospheric burden of VOC oxidants and secondary organic aerosols. Here, we argue, based on preliminary evidence from several opportunistic measurement sources, that chemical signatures of stress can be identified and quantified at the ecosystem scale. We also outline future endeavors that we see as next steps toward uncovering quantitative signatures of stress, including new advances in both VOC data collection and analysis of "big data.

A phenotype of atypical apraxia of speech in a family carrying SQSTM1 mutation.

SQSTM1 mutations, coding for the p62 protein, were identified as a monogenic cause of Paget disease of bone and of amyotrophic lateral sclerosis. More recently, SQSTM1 mutations were identified in few families with frontotemporal dementia. We report a new family carrying SQSTM1 mutation and presenting with a clinical phenotype of speech apraxia or atypical behavioral disorders, associated with early visuo-contructional deficits. This study further supports the implication of SQSTM1 in frontotemporal dementia, and enlarges the phenotypic spectrum associated with SQSTM1 mutations

A MODIS Photochemical Reflectance Index (PRI) as an Estimator of Isoprene Emissions in a Temperate Deciduous Forest

The quantification of isoprene and monoterpene emissions at the ecosystem level with available models and field measurements is not entirely satisfactory. Remote-sensing techniques can extend the spatial and temporal assessment of isoprenoid fluxes. Detecting the exchange of biogenic volatile organic compounds (BVOCs) using these techniques is, however, a very challenging goal. Recent evidence suggests that a simple remotely sensed index, the photochemical reflectance index (PRI), which is indicative of light-use efficiency, relative pigment levels and excess reducing power, is a good indirect estimator of foliar isoprenoid emissions. We tested the ability of PRI to assess isoprenoid fluxes in a temperate deciduous forest in central USA throughout the entire growing season and under moderate and extreme drought conditions. We compared PRI time series calculated with MODIS bands to isoprene emissions measured with eddy covariance. MODIS PRI was correlated with isoprene emissions for most of the season, until emissions peaked. MODIS PRI was also able to detect the timing of the annual peak of emissions, even when it was advanced in response to drought conditions. PRI is thus a promising index to estimate isoprene emissions when it is complemented by information on potential emission. It may also be used to further improve models of isoprene emission under drought and other stress conditions. Direct estimation of isoprene emission by PRI is, however, limited, because PRI estimates LUE, and the relationship between LUE and isoprene emissions can be modified by severe stress conditions

A MODIS Photochemical Reflectance Index (PRI) as an Estimator of Isoprene Emissions in a Temperate Deciduous Forest

The quantification of isoprene and monoterpene emissions at the ecosystem level with available models and field measurements is not entirely satisfactory. Remote-sensing techniques can extend the spatial and temporal assessment of isoprenoid fluxes. Detecting the exchange of biogenic volatile organic compounds (BVOCs) using these techniques is, however, a very challenging goal. Recent evidence suggests that a simple remotely sensed index, the photochemical reflectance index (PRI), which is indicative of light-use efficiency, relative pigment levels and excess reducing power, is a good indirect estimator of foliar isoprenoid emissions. We tested the ability of PRI to assess isoprenoid fluxes in a temperate deciduous forest in central USA throughout the entire growing season and under moderate and extreme drought conditions. We compared PRI time series calculated with MODIS bands to isoprene emissions measured with eddy covariance. MODIS PRI was correlated with isoprene emissions for most of the season, until emissions peaked. MODIS PRI was also able to detect the timing of the annual peak of emissions, even when it was advanced in response to drought conditions. PRI is thus a promising index to estimate isoprene emissions when it is complemented by information on potential emission. It may also be used to further improve models of isoprene emission under drought and other stress conditions. Direct estimation of isoprene emission by PRI is, however, limited, because PRI estimates LUE, and the relationship between LUE and isoprene emissions can be modified by severe stress conditions

A MODIS Photochemical Reflectance Index (PRI) as an Estimator of Isoprene Emissions in a Temperate Deciduous Forest

The quantification of isoprene and monoterpene emissions at the ecosystem level with available models and field measurements is not entirely satisfactory. Remote-sensing techniques can extend the spatial and temporal assessment of isoprenoid fluxes. Detecting the exchange of biogenic volatile organic compounds (BVOCs) using these techniques is, however, a very challenging goal. Recent evidence suggests that a simple remotely sensed index, the photochemical reflectance index (PRI), which is indicative of light-use efficiency, relative pigment levels and excess reducing power, is a good indirect estimator of foliar isoprenoid emissions. We tested the ability of PRI to assess isoprenoid fluxes in a temperate deciduous forest in central USA throughout the entire growing season and under moderate and extreme drought conditions. We compared PRI time series calculated with MODIS bands to isoprene emissions measured with eddy covariance. MODIS PRI was correlated with isoprene emissions for most of the season, until emissions peaked. MODIS PRI was also able to detect the timing of the annual peak of emissions, even when it was advanced in response to drought conditions. PRI is thus a promising index to estimate isoprene emissions when it is complemented by information on potential emission. It may also be used to further improve models of isoprene emission under drought and other stress conditions. Direct estimation of isoprene emission by PRI is, however, limited, because PRI estimates LUE, and the relationship between LUE and isoprene emissions can be modified by severe stress conditions

Response to Biologic Drugs in Patients with Rheumatoid Arthritis and Antidrug Antibodies

Importance: There are conflicting data on the association of antidrug antibodies with response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA). Objective: To analyze the association of antidrug antibodies with response to treatment for RA. Design, Setting, and Participants: This cohort study analyzed data from the ABI-RA (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients) multicentric, open, prospective study of patients with RA from 27 recruiting centers in 4 European countries (France, Italy, the Netherlands, and the UK). Eligible patients were 18 years or older, had RA diagnosis, and were initiating a new bDMARD. Recruitment spanned from March 3, 2014, to June 21, 2016. The study was completed in June 2018, and data were analyzed in June 2022. Exposures: Patients were treated with a new bDMARD: adalimumab, infliximab (grouped as anti-tumor necrosis factor [TNF] monoclonal antibodies [mAbs]), etanercept, tocilizumab, and rituximab according to the choice of the treating physician. Main Outcomes and Measures: The primary outcome was the association of antidrug antibody positivity with EULAR (European Alliance of Associations for Rheumatology; formerly, European League Against Rheumatism) response to treatment at month 12 assessed through univariate logistic regression. The secondary end points were the EULAR response at month 6 and at visits from month 6 to months 15 to 18 using generalized estimating equation models. Detection of antidrug antibody serum levels was performed at months 1, 3, 6, 12, and 15 to 18 using electrochemiluminescence (Meso Scale Discovery) and drug concentration for anti-TNF mAbs, and etanercept in the serum was measured using enzyme-linked immunosorbent assay. Results: Of the 254 patients recruited, 230 (mean [SD] age, 54.3 [13.7] years; 177 females [77.0%]) were analyzed. At month 12, antidrug antibody positivity was 38.2% in patients who were treated with anti-TNF mAbs, 6.1% with etanercept, 50.0% with rituximab, and 20.0% with tocilizumab. There was an inverse association between antidrug antibody positivity (odds ratio [OR], 0.19; 95% CI, 0.09-0.38; P <.001) directed against all biologic drugs and EULAR response at month 12. Analyzing all the visits starting at month 6 using generalized estimating equation models confirmed the inverse association between antidrug antibody positivity and EULAR response (OR, 0.35; 95% CI, 0.18-0.65; P <.001). A similar association was found for tocilizumab alone (OR, 0.18; 95% CI, 0.04-0.83; P =.03). In the multivariable analysis, antidrug antibodies, body mass index, and rheumatoid factor were independently inversely associated with response to treatment. There was a significantly higher drug concentration of anti-TNF mAbs in patients with antidrug antibody-negative vs antidrug antibody-positive status (mean difference, -9.6 [95% CI, -12.4 to -6.9] mg/L; P < 001). Drug concentrations of etanercept (mean difference, 0.70 [95% CI, 0.2-1.2] mg/L; P =.005) and adalimumab (mean difference, 1.8 [95% CI, 0.4-3.2] mg/L; P =.01) were lower in nonresponders vs responders. Methotrexate comedication at baseline was inversely associated with antidrug antibodies (OR, 0.50; 95% CI, 0.25-1.00; P =.05). Conclusions and Relevance: Results of this prospective cohort study suggest an association between antidrug antibodies and nonresponse to bDMARDs in patients with RA. Monitoring antidrug antibodies could be considered in the treatment of these patients, particularly nonresponders to biologic RA drugs

Démences : où sont les corps de Lewy ?

La démence à corps de Lewy (DCL) est la deuxième cause de démence dégénérative du sujet âgé, dans les grandes séries autopsiques. Dans la réalité quotidienne des centres mémoire pourtant, la DCL représente une faible proportion des diagnostics cliniques, avec une forte disparité entre les centres. Plusieurs raisons peuvent rendre compte de la faible sensibilité du diagnostic de DCL : l’imprécision et la subjectivité des critères diagnostiques existants ; la place insuffisante donnée à certains signes non-moteurs (troubles du comportement en sommeil paradoxal, dysautonomie) ; enfin et surtout l’association quasi constante de la pathologie de Lewy à une pathologie de type Alzheimer, qui domine rapidement le phénotype clinique. À l’heure de l’essor des thérapies ciblées contre les agrégats protéiques, de nouvelles échelles cliniques permettant d’appréhender la coexistence de la pathologie de Lewy dans la maladie d’Alzheimer sont plus que jamais nécessaires